Comparison · NCT02797067-3efdc2dc
Indomethacin vs Glycerin: the Incidence of Post-ESWL Pancreatitis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Indomethacin vs Glycerin: the Incidence of Post-ESWL Pancreatitis. Trial comparisons, record NCT02797067-3efdc2dc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02797067-3efdc2dc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0876 | 0.0687 | 0.111 | wilson | |
| Risk in group 2 | 0.123 | 0.1 | 0.149 | wilson | |
| Risk difference, group 1 minus group 2 | -0.035 | -0.0678 | -0.00249 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.714 | 0.522 | 0.978 | log | |
| Odds ratio, group 1 over group 2 | 0.687 | 0.484 | 0.974 | log | |
| Number needed to treat, for one fewer participant with the outcome on Indomethacin than on Glycerin | 28.5 | 14.8 | 402 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Indomethacin | Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.~indomethacin suppository: 100mg rectal indomethacin 30min before ESWL | 60 | 685 | OG000 |
| Group 2 | Glycerin | Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.~Glycerin Suppository: 30min before ESWL | 84 | 685 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- the Incidence of Post-ESWL Pancreatitis
- Description
Patients were identified as post-ESWL pancreatitis if meeting two out of three criteria: pain consistent with acute pancreatitis; amylase or lipase\>3 times normal limit; characteristic findings on imaging, in according to the Revised Atlanta International consensus.
- Time frame
- up to 1 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rectal Indomethacin to Prevent Post ESWL-pancreatitis
- NCT number
- NCT02797067
- Phases
- PHASE4
- Conditions
- Pancreatitis
- Interventions
- indomethacin suppository, Glycerin Suppository
- Lead sponsor
- Changhai Hospital
- Results first posted
- 2022-05-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02797067?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02797067-3efdc2dc